Promising Developments in Tackling Resistance to Blood Cancer Drugs
A new drug with the potential to reverse resistance to immunotherapy has been developed by scientists at the University of […]
Tags: antibodies, BioInvent International Aktiebolag, blood cancers, cancer, CANCER RESEARCH TECHNOLOGY LIMITED, Cancer Research UK, Cancer treatments, Chief Scientific Officer, Chris Bunce, chronic lymphocytic leukaemia, directly killing cancer, Director at Leukaemia & Lymphoma Research Research, Dr Ingrid Teige, Emma Smith, Health/Medical/Pharmaceuticals, Hodgkin's lymphoma, honorary Professor, Immune system, immunology, Immunotherapy, Ingrid Teige, leukaemia, Lymphocytic leukemia, Lymphoma, Mark Cragg, medicine, Monoclonal antibodies, Monoclonal antibody therapy, Non-Hodgkin lymphoma, non-Hodgkin lymphomas, patient's disease, professor, Professor Björn Frendéus, Professor of Experimental Cancer Research, Rituximab, Southampton, sweden, targeted tumor, therapeutics for blood cancers, treatment for several types of cancer, Tumours, University of Southampton, white blood cell cancers
XIENCE
Patients treated with XIENCE V in SPIRIT III trial experience better long-term clinical outcomes, lower rates of stent thrombosis than patients treated with TAXUS.
